{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:33:53Z","timestamp":1791477233969,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interstitial lung disease (ILD) is a heterogeneous group of mainly chronic lung diseases differing in disease course and prognosis. For most subtypes, evidence on relevance and outcomes of hospitalisations is lacking.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using German claims data we investigated number of hospitalisations (zero-inflated-negative-binomial models providing rate ratios (RR)) and time to first hospitalisation (Cox proportional-hazard models providing hazard ratios (RR)) for nine ILD-subtypes. Models were stratified by ILD-related and non-ILD-related hospitalisations. We adjusted for age, gender, ILD-subtype, ILD-relevant comorbidities and ILD-medication (immunosuppressive drugs, steroids, anti-fibrotic drugs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 36,816 ILD-patients (mean age 64.7\u2009years, 56.2% male, mean observation period 9.3 quarters), 71.2% had non-ILD-related and 56.6% ILD-related hospitalisations. We observed more and earlier non-ILD-related hospitalisations in ILD patients other than sarcoidosis. Medical ILD-treatment was associated with increased frequency and in case of late initiation, earlier (non-)ILD-related hospitalisations. Comorbidities were associated with generally increased hospitalisation frequency except for COPD (RR\u2009=\u20090.90) and PH (RR\u2009=\u20090.94) in non-ILD-related and for lung cancer in ILD-related hospitalisations (RR\u2009=\u20090.89). Coronary heart disease was linked with earlier (ILD-related: HR\u2009=\u20091.17, non-ILD-related HR\u2009=\u20091.19), but most other conditions with delayed hospitalisations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Hospitalisations are frequent across all ILD-subtypes. The hospitalisation risk might be reduced independently of the subtype by improved management of comorbidities and improved pharmacological and non-pharmacological ILD therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-020-01335-x","type":"journal-article","created":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T05:03:12Z","timestamp":1585198992000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment \u2013 a German claims data analysis"],"prefix":"10.1186","volume":"21","author":[{"given":"Julia","family":"W\u00e4lscher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa","family":"Schwarzkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,26]]},"reference":[{"issue":"2","key":"1335_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","volume":"165","author":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias","year":"2002","unstructured":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165(2):277\u2013304.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1335_CR2","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000329893","volume":"83","author":"R Tachikawa","year":"2012","unstructured":"Tachikawa R, Tomii K, Ueda H, Nagata K, Nanjo S, Sakurai A, et al. Clinical features and outcome of acute exacerbation of interstitial pneumonia: collagen vascular diseases-related versus idiopathic. Respiration. 2012;83(1):20\u20137.","journal-title":"Respiration."},{"issue":"9","key":"1335_CR3","doi-asserted-by":"publisher","first-page":"e003132","DOI":"10.1136\/bmjopen-2013-003132","volume":"3","author":"H Hozumi","year":"2013","unstructured":"Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, et al. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open. 2013;3(9):e003132.","journal-title":"BMJ Open"},{"issue":"5","key":"1335_CR4","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.humpath.2011.06.001","volume":"43","author":"LP Hariri","year":"2012","unstructured":"Hariri LP, Mino-Kenudson M, Shea B, Digumarthy S, Onozato M, Yagi Y, et al. Distinct histopathology of acute onset or abrupt exacerbation of hypersensitivity pneumonitis. Hum Pathol. 2012;43(5):660\u20138.","journal-title":"Hum Pathol"},{"issue":"7","key":"1335_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1164\/rccm.200703-463PP","volume":"176","author":"HR Collard","year":"2007","unstructured":"Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636\u201343.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1335_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1378\/chest.13-2424","volume":"147","author":"AW Brown","year":"2015","unstructured":"Brown AW, Fischer CP, Shlobin OA, Buhr RG, Ahmad S, Weir NA, et al. Outcomes after hospitalization in idiopathic pulmonary fibrosis. Chest. 2015;147(1):173\u20139.","journal-title":"Chest."},{"issue":"3","key":"1335_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00103-012-1626-9","volume":"56","author":"J Jaunzeme","year":"2013","unstructured":"Jaunzeme J, Eberhard S, Geyer S. How \u201crepresentative\u201d are SHI (statutory health insurance) data? Demographic and social differences and similarities between an SHI-insured population, the population of Lower Saxony, and that of the Federal Republic of Germany using the example of the AOK in Lower Saxony. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56(3):447\u201354.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"},{"issue":"2","key":"1335_CR8","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, et al. Good practice of secondary data analysis (GPS): guidelines and recommendations. Gesundheitswesen. 2015;77(2):120\u20136.","journal-title":"Gesundheitswesen."},{"issue":"6","key":"1335_CR9","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","volume":"196","author":"B Ley","year":"2017","unstructured":"Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196(6):756\u201361.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1335_CR10","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12931-018-0769-0","volume":"19","author":"L Schwarzkopf","year":"2018","unstructured":"Schwarzkopf L, Witt S, Waelscher J, Polke M, Kreuter M. Associations between comorbidities, their treatment and survival in patients with interstitial lung diseases - a claims data analysis. Respir Res. 2018;19(1):73.","journal-title":"Respir Res"},{"issue":"5","key":"1335_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383.","journal-title":"J Chronic Dis"},{"issue":"4","key":"1335_CR12","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","volume":"46","author":"G Raghu","year":"2015","unstructured":"Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46(4):1113\u201330.","journal-title":"Eur Respir J"},{"key":"1335_CR13","doi-asserted-by":"publisher","unstructured":"Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26(143):160027. https:\/\/doi.org\/10.1183\/16000617.0027-2016. Print 2017 Jan.","DOI":"10.1183\/16000617.0027-2016"},{"key":"1335_CR14","first-page":"309","volume":"8","author":"BG Fulton","year":"2015","unstructured":"Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med. 2015;8:309\u201318.","journal-title":"Int J Gen Med"},{"issue":"3","key":"1335_CR15","doi-asserted-by":"publisher","first-page":"e0151425","DOI":"10.1371\/journal.pone.0151425","volume":"11","author":"M Kreuter","year":"2016","unstructured":"Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One. 2016;11(3):e0151425.","journal-title":"PLoS One"},{"key":"1335_CR16","volume-title":"Accounting for excess zeros and sample selection in poisson and negative binomial regression models","author":"W Greene","year":"1994","unstructured":"Greene W. Accounting for excess zeros and sample selection in poisson and negative binomial regression models. New York: New York University, Leonard N. Stern School of Business, Department of Economics; 1994."},{"issue":"1","key":"1335_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev.publhealth.20.1.145","volume":"20","author":"LD Fisher","year":"1999","unstructured":"Fisher LD, Lin DY. Time-dependent covariates in the cox proportional-hazards regression model. Annu Rev Public Health. 1999;20(1):145\u201357.","journal-title":"Annu Rev Public Health"},{"issue":"1","key":"1335_CR18","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1183\/09031936.00217614","volume":"46","author":"J Behr","year":"2015","unstructured":"Behr J, Kreuter M, Hoeper MM, Wirtz H, Klotsche J, Koschel D, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J. 2015;46(1):186\u201396.","journal-title":"Eur Respir J"},{"issue":"1","key":"1335_CR19","doi-asserted-by":"publisher","first-page":"e0166462","DOI":"10.1371\/journal.pone.0166462","volume":"12","author":"V Cottin","year":"2017","unstructured":"Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, et al. Burden of idiopathic pulmonary fibrosis progression: a 5-year longitudinal follow-up study. PLoS One. 2017;12(1):e0166462.","journal-title":"PLoS One"},{"issue":"5","key":"1335_CR20","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"1335_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/2040622318790197","volume":"9","author":"EV Arkema","year":"2018","unstructured":"Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Ther Adv Chronic Dis. 2018;9(11):227\u201340.","journal-title":"Ther Adv Chronic Dis"},{"issue":"3","key":"1335_CR22","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00103-012-1626-9","volume":"56","author":"J Jaunzeme","year":"2013","unstructured":"Jaunzeme J, Eberhard S, Geyer S. Wie \u201crepr\u00e4sentativ\u201d sind GKV-Daten? Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz. 2013;56(3):447\u201354.","journal-title":"Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12931-020-01335-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-020-01335-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T20:21:36Z","timestamp":1616703696000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-020-01335-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,26]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1186\/s12931-020-01335-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,26]]},"assertion":[{"value":"17 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Such analyses do not require consultation of an ethics committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JW received personal fees from Boehringer Ingelheim and Roche.MK received research grants and personal fees from Boehringer Ingelheim and Roche.The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}